Cargando…

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

BACKGROUND: Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies. Ongoing clinical trials are studying its activity in other malignancies, such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casadei Gardini, Andrea, Chiadini, Elisa, Faloppi, Luca, Marisi, Giorgia, Delmonte, Angelo, Scartozzi, Mario, Loretelli, Cristian, Lucchesi, Alessandro, Oboldi, Devil, Dubini, Alessandra, Frassineti, Giovanni Luca, Ulivi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937544/ https://www.ncbi.nlm.nih.gov/pubmed/27388325 http://dx.doi.org/10.1186/s12885-016-2463-2

Ejemplares similares

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease
por: Casadei Gardini, Andrea, et al.
Publicado: (2013)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Ulivi, Paola, et al.
Publicado: (2021)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2023)

Primary Hyperparathyroidism: Imaging to Pathology
por: Piciucchi, Sara, et al.
Publicado: (2012)

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
por: Capelli, Laura, et al.
Publicado: (2016)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
por: Caputo, Francesco, et al.
Publicado: (2019)

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
por: De Matteis, Serena, et al.
Publicado: (2019)

(1)H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages
por: Casadei-Gardini, Andrea, et al.
Publicado: (2020)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Recent Research on Gastrointestinal Carcinoma
por: Rovesti, Giulia, et al.
Publicado: (2021)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
por: Yang, Yang, et al.
Publicado: (2017)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
por: Wei, Xue-Wu, et al.
Publicado: (2022)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
por: Sapena, Víctor, et al.
Publicado: (2022)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
por: Scartozzi, Mario, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_maho38j9i4eu83j6jdb78dfupp